Delivery Order SPE2DB22D9316-SPE2DB24FYP40
- Not listed
- This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $5,262.76 contract is for the delivery of TYSABRI 300 MG/15 ML VIAL 15ML pharmaceutical products. The award is not associated with a set-aside program. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, enabling the agency to issue delivery...
- The Defense Logistics Agency (DLA) awarded a $51,581.80 firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of TYSABRI 300 MG/15 ML VIAL 15ML. This delivery order is part of a larger indefinite delivery vehicle (IDV) contract, SPE2DB24FPQG7, valued at up to $4,999,999 through 2025, which enables DLA to issue delivery orders for a broad range of pharmaceutical products to support military medical facilities. DMS Pharmaceutical...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,316.36 firm fixed-price contract is for the delivery of Tysabri 300 mg/15 ml vials. DMS Pharmaceutical Group holds a larger, single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to issue delivery...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $52,627.70 contract is for the supply of Tysabri 300 mg/15 ml vials, with a performance period through April 28, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $51,581.80 contract is for the delivery of TYSABRI 300 MG/15 ML vials to support the medical supply needs of military healthcare facilities. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which allows...
- This is a firm fixed-price delivery order valued at $10,525.54 awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA). The contract is for the delivery of TYSABRI 300 MG/15 ML VIAL 15ML, a specialty pharmaceutical product, with a period of performance through February 25, 2025. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of branded and generic prescription drugs,...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $25,547.76 contract is for the delivery of Tysabri 300 mg/15 ml vials. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $59,611.44, is for the delivery of TYSABRI 300 MG/15 ML VIAL 15ML, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid...
- This is a delivery order valued at $10,316.36 awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the supply of Tysabri 300 mg/15 ml vials with a completion date of June 11, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to DMS Pharmaceutical Group by the DLA under the SPE2DB program, valued at up to $499,999,999 through...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $10,316.36 firm fixed-price delivery order covers the supply of Tysabri 300 mg/15 ml vial, with an ultimate completion date of October 31, 2024. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group to provide a comprehensive...
- SPE2DB22D9316Indefinite Delivery Contract
- SPE2DB22D9316-SPE2DB24FYP40Delivery Order
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the SPE2DB procurement program. The contract is for $10,316.36 and covers the delivery of TYSABRI 300 MG/15 ML VIAL 15ML, with a period of performance through July 2, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This single-award vehicle allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply needs of military health facilities worldwide. The contract award does not have a set-aside designation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 6/10/24 |